Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol-Myers Squibb Breaks Oral Hep C Treatment Barrier

This article was originally published in The Pink Sheet Daily

Executive Summary

The proof-of-concept news is based on the finding that four of 11 patients (36%) in the all-oral arm of an exploratory 21-patient trial achieved a sustained virologic response 12 weeks after completion of treatment, though in the other arm, which added peginterferon and ribavirin to the duo, all 10 patients reached that cure threshold.


Related Content

High-Premium Buyouts Continue In Hepatitis C Space; Are Idenix And Achillion Next?
HCV Buyup Continues As Bristol Offers $2.5 Billion For Inhibitex
Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts